Literature DB >> 16272910

Multiple organ dysfunction syndrome after multiple trauma.

Colleen R Walsh1.   

Abstract

Multiple organ dysfunction syndrome (MODS) is a serious, often fatal, sequel to multiple trauma. Prolonged shock states, severe sepsis, acute pancreatitis, acute renal failure, severe burns, ischemic conditions, and acute respiratory distress syndrome have been implicated in the development of MODS. Despite advances in critical care therapies and infection control practices, severe sepsis remains a major health problem, with an estimated mortality rate of 30-50% (Ely, Kleinpell, & Goyett, 2003). The purposes of this article are to describe the pathophysiologic changes that lead to the development of MODS and discuss strategies to prevent the development of MODS and to treat MODS if it develops.

Entities:  

Mesh:

Year:  2005        PMID: 16272910     DOI: 10.1097/00006416-200509000-00006

Source DB:  PubMed          Journal:  Orthop Nurs        ISSN: 0744-6020            Impact factor:   0.913


  4 in total

1.  Matrix metalloproteinase-9 as new biomarkers of severity in multiple organ dysfunction syndrome caused by trauma and infection.

Authors:  Lin Teng; Min Yu; Jun-ming Li; Hua Tang; Jing Yu; Li-hua Mo; Jing Jin; Xian-zhe Liu
Journal:  Mol Cell Biochem       Date:  2011-10-01       Impact factor: 3.396

Review 2.  Early prevention of trauma-related infection/sepsis.

Authors:  Xiao-Yuan Ma; Li-Xing Tian; Hua-Ping Liang
Journal:  Mil Med Res       Date:  2016-11-08

3.  Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction syndrome.

Authors:  B Tuerdi; L Zuo; H Sun; K Wang; Z Wang; G Li
Journal:  Braz J Med Biol Res       Date:  2017-11-17       Impact factor: 2.590

4.  Assessment of extravascular lung water by measuring the number of pulmonary ultrasound B-lines before and after CBP in patients with MODS.

Authors:  Guangke Cao; Yu Wu; Yuliang Zhao; Ling Wang; Yang Zhang
Journal:  Medicine (Baltimore)       Date:  2021-01-08       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.